SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD)	Adenosine A_{2A} receptor ($ADORA_{2A}$); monoamine oxidase B (MAO-B)	*In vitro* studies suggest dual antagonists of $ADORA_{2A}$ and MAO-B could be useful for treating PD. Both proteins are known targets in PD. *In vitro*, the lead molecule from a series of benzothiazinones selectively antagonized human $ADORA_{2A}$ with an IC_{50} value of 39.5 nM and MAO-B with an IC_{50} value of 34.9 nM. Next steps include evaluating other members of the compound series in mice. Kyowa Hakko Kirin Co. Ltd. markets the $ADORA_{2A}$ antagonist Nouriast istradefylline to treat PD. At least seven other companies have $ADORA_{2A}$ antagonists in Phase III or earlier testing to treat PD. Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S market Azilect rasagiline, an irreversible selective inhibitor of MAO-B, to treat PD. Valeant Pharmaceuticals International Inc. markets the MAO-B inhibitor Zelapar selegiline for the same indication. At least six other MAO-B inhibitors are in Phase III or earlier testing to treat PD.	Compound series covered by pending patents; available for licensing	Stößel, A. *et al. J. Med. Chem.*; published online April 30, 2013; doi:10.1021/jm400336x **Contact:** Christa E. Müller, PharmaCenter Bonn, Bonn, Germany e-mail: christa.mueller@uni-bonn.de **Contact:** Michael Gütschow, same affiliation as above e-mail: guetschow@uni-bonn.de

SciBX 6(21); doi:10.1038/scibx.2013.526
Published online May 30, 2013